A Chong Kun Dang Pharmaceutical Corp. patent describes new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors potentially useful for the treatment of cancer, rheumatoid arthritis, multiple sclerosis, Crohn’s disease, ulcerative colitis, graft-vs.-host disease, systemic lupus erythematosus and osteoarthritis, among others.